Why Farbe Firma is the Top Manufacturer of Dipyridamole Injection
- Maulik Sudani
- 16 hours ago
- 7 min read
Last Updated: June 13, 2026
TL;DR: Dipyridamole Injection — a sterile, clear yellow aqueous solution of dipyridamole, a platelet aggregation inhibitor and coronary vasodilator, supplied commonly as a 10 mg/2 mL ampoule (5 mg/mL) for dilution and intravenous infusion — is best known as a pharmacologic stress agent used in place of exercise during myocardial perfusion imaging (thallium or other radionuclide cardiac stress testing) in patients who cannot exercise adequately. Dipyridamole must be diluted before intravenous use, is light-sensitive, and must remain a clear solution free of particulates, so each ampoule must deliver an exact, sterile, particulate-free dose at the labelled concentration. Its safety and shelf life depend on a precise stability-indicating assay, a tightly controlled impurity and degradation profile, accurate pH and fill-volume control, light protection, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Dipyridamole Injection at our Gujarat, India facility and supplies it to hospital pharmacy, cardiology, nuclear-medicine and diagnostic-imaging services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Platelet aggregation inhibitor and coronary vasodilator — Dipyridamole Injection is used chiefly as an intravenous pharmacologic stress agent during myocardial perfusion imaging in patients unable to exercise, producing coronary vasodilation that reveals perfusion differences, and is also recognised for its antiplatelet action.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, light-protected solution compounding and ampoule filling lines, dedicated control of the stability-indicating assay, the impurity profile, solution pH, fill volume, particulate and endotoxin for a light-sensitive low-volume parenteral concentrate, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready ampoule packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Dipyridamole Injection Demands a Premium Manufacturer
Dipyridamole Injection occupies a specialised but important place in cardiology and nuclear medicine across every market. It is the intravenous pharmacologic stress agent that clinicians reach for when a patient who needs myocardial perfusion imaging cannot exercise adequately on a treadmill or bicycle — in the work-up of suspected coronary artery disease, where dipyridamole produces coronary vasodilation that unmasks differences in perfusion between healthy and stenosed territories during thallium or other radionuclide cardiac scanning. Diluted from a small-volume ampoule and given as a controlled intravenous infusion, dipyridamole acts on the coronary circulation to allow the imaging study to do its work; the molecule is also long recognised for its antiplatelet, aggregation-inhibiting action. In each of these settings the dose delivered from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, because the diagnostic result and patient safety both depend on an accurately delivered dose.
That clinical reality places real demands on the manufacturer. Dipyridamole is presented as a low-volume aqueous concentrate — typically 10 mg in 2 mL — that must be diluted before intravenous use and must remain a clear, yellow solution free of particulates throughout shelf life. The assay must be exact; the impurity and degradation profile must stay within tight limits; the pH and the deliverable volume must be controlled tightly so each ampoule gives the labelled dose; the solution must be free of visible and sub-visible particulates and low in endotoxin; the product must be protected from light because dipyridamole is light-sensitive; and it must be sealed in an ampoule whose container-closure integrity holds across shelf life. Choosing a Dipyridamole Injection manufacturer that treats the stability-indicating assay, pH and fill-volume control, light protection, the validated sterilisation route, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Dipyridamole Injection Manufacturer Apart
A world-class manufacturer of Dipyridamole Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of dipyridamole with the tight related-substance and degradation-product control by HPLC that a light-sensitive parenteral demands, a robust, validated aseptic solution-fill process — with terminal moist-heat sterilisation where the formulation and container permit it, otherwise sterile filtration and aseptic filling — that protects the assay, the pH and the clarity of the solution, and tender-ready dossier support for a hospital-formulary, diagnostic-imaging product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade dipyridamole sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend both the assay and the dose. The bulk solution is compounded in water-for-injection at the controlled pH that keeps dipyridamole stable and in solution, sterile-filtered through 0.22 µm membrane, and filled into ampoules under light-protected ISO Class 5 conditions, with the validated sterilisation route — terminal moist-heat where qualified, otherwise full aseptic processing — locked in the master batch record. Filled ampoules are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm dipyridamole assay by validated HPLC, the related-substance profile, solution pH, deliverable volume, visible and sub-visible particulate matter, and endotoxin is held well within limits so the injection is safe for intravenous administration. Because dipyridamole is light-sensitive, the compounding, holding and filling steps and the finished pack are all protected from light.
Quality Systems Behind Every Dipyridamole Injection
Every Farbe Firma Dipyridamole Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of dipyridamole against pharmacopoeial reference standards, control of related substances and degradation products by HPLC, solution pH, deliverable (fill) volume, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule format. Certificates of analysis are issued with full traceability back to the API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, light-protected (low-actinic) compounding and filling areas, validated ampoule-filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because dipyridamole is light-sensitive and its assay, pH, clarity and particulate burden drive both diagnostic reliability and safety, we treat the stability-indicating HPLC assay, the solution pH, the deliverable volume and the related-substance profile as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and the product is protected from light through its ampoule labelling and secondary packaging.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Dipyridamole Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad small-volume parenteral portfolio across cardiovascular, diagnostic, critical-care and supportive-care categories. For Dipyridamole Injection specifically, we supply 10 mg/2 mL (5 mg/mL) single-dose ampoules of sterile solution under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Dipyridamole Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, light-protected artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance and degradation control, pH and solubility design, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose control, light-protection strategy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a light-sensitive diagnostic parenteral where assay accuracy, pH and particulate control directly govern both the diagnostic result and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Dipyridamole Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Dipyridamole Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, light-protected solution compounding and ampoule filling lines, validated sterilisation, qualified water-for-injection systems, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Dipyridamole Injection do you supply?
Our standard presentation is the 10 mg/2 mL (5 mg/mL) single-dose ampoule of sterile dipyridamole solution, a concentrate to be diluted before intravenous infusion. Custom strengths, fill configurations, ampoule or vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Dipyridamole Injection mainly used for?
Dipyridamole Injection is used chiefly as a pharmacologic stress agent in myocardial perfusion imaging — in place of exercise — for patients who cannot exercise adequately, producing coronary vasodilation that helps reveal perfusion differences during thallium or other radionuclide cardiac stress testing. Dipyridamole is also recognised as a platelet aggregation inhibitor. It must be diluted before intravenous use; Farbe Firma protects the solution from light and verifies assay, clarity, deliverable volume and particulate matter at release.
Can Farbe Firma support country-specific registrations for Dipyridamole Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Dipyridamole Injection contract manufacturing?
MOQs vary by strength, ampoule size, sterilisation route, label complexity and dossier requirements. For our small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments